Noopept France: 0 medicinal products found in the French Public Medicines Database on 13 October 2026 under Noopept, omberacetam or ombéracétam. This proves neither authorised over-the-counter sale nor efficacy: no robust benefit has been established for improving memory or focus in a healthy adult.
Noopept: the short answer
Noopept, also called omberacetam or GVS-111, is a synthetic pharmacological substance. The absence of an authorised medicine in France does not translate into “legal and tolerated for personal use”. Our guide to nootropics and their status in France puts Noopept in context alongside supplements and prescription medicines.
On efficacy, the conclusion is just as clear: no solid clinical evidence shows that Noopept improves memory, focus or learning in a healthy person. The available literature is mainly preclinical. The main clinical studies concern vascular or trauma-related cognitive disorders. Exploratory data in healthy subjects, detailed below, do not demonstrate a benefit for everyday studying or work.
This guide addresses four decisions: status in France and the European Union, evidence on memory, risks, then a comparison of Noopept vs piracetam. A seller’s product page settles none of these questions.
What is verified, and what remains uncertain
To avoid turning a poorly documented molecule into a marketing promise, you need to separate facts from extrapolations:
| Question | Verified answer as of 13 October 2026 | Level of uncertainty |
|---|---|---|
| French marketing authorisation for Noopept | No medicinal product identified under Noopept, omberacetam or ombéracétam in the French public database | Absence from the database does not replace individual legal advice |
| Authorised use in the EU | The EDQM states in June 2025 that its use is not authorised in the EU | Report reviewed in October 2026, not an exhaustive legal database for every country |
| Sale as a medicine in France | No authorised medicine identified under this name | Legal classification also depends on presentation and the claimed function |
| Personal importation by post | Conditions and sometimes prior ANSM authorisation apply | Depends on the country of origin, local authorisation and prescription |
| Efficacy in healthy adults | Not demonstrated | Very high, due to the lack of robust trials |
| Long-term safety | Not established | Very high |
| Superiority over piracetam | Not demonstrated for cognitive enhancement in a healthy subject | High |
| “1,000 times more potent” | Misleading phrase if describing the perceived or clinical effect | Major extrapolation from different doses and models |
This page provides editorial and scientific analysis. For a personal decision about a product, an import or a cognitive symptom, consult a doctor, pharmacist or the ANSM.
What is Noopept, or omberacetam?
Noopept is the trade name associated with omberacetam, a synthetic compound derived from a dipeptide. Its chemical name is N-phenylacetyl-L-prolylglycine ethyl ester. It was developed in Russia and also appears in the literature under the code GVS-111.
Noopept is not a racetam in the strict structural sense. Classic racetams, including piracetam, share a pyrrolidone core. Nevertheless, Noopept is often grouped alongside them because its developers studied it as a nootropic and neuroprotective agent.
This historical connection encourages two shortcuts:
- a molecule active at a lower quantity must be more potent
- a mechanism observed in animals would predict a memory improvement in humans
Neither holds up without appropriate clinical trials. The guide to racetams, their evidence and their risks · FR explains why these neighbouring families do not automatically share efficacy.
What do the studies really say about memory?
Human clinical studies: what they allow us to say
A comparison published in 2009 between Noopept and piracetam concerns cognitive disorders of vascular or traumatic origin. The bibliographic record consulted has no abstract: it confirms the topic and population, but does not allow verification of the sample size or a precise assessment of the results. I therefore draw no efficacy figures from it.
Another prospective open-label study from 2011 describes 60 patients after a stroke and reports improvement on some cognitive tests. An open-label study in a patient population does not demonstrate a memory gain in a healthy person.
There are also data in healthy subjects: a 2007 study in young volunteers assessed adaptation to cold, heat and hypoxia in a climate chamber. The abstract reports favourable signals, without sufficiently documenting controls, randomisation or sample size to support a recommendation for everyday memory. A 2018 study in older teachers combined Noopept and self-massage, without isolating a benefit compared with placebo.
Limited human data does not mean there are no human studies at all. During this update, I did not identify a robust, properly controlled and replicated trial showing a benefit for working memory, attention or learning in healthy adults. Exploratory signals do not meet that standard.
BDNF and NGF: a signal in rats is not a human result
A 2008 study observed changes in messenger RNA expression for neurotrophic factors, including BDNF and NGF, in the hippocampus of rats after Noopept administration. Other studies explore neuron cultures exposed to oxidative stress.
These studies are useful for generating hypotheses. They do not demonstrate the following claims:
- Noopept “massively increases” BDNF in humans
- more BDNF automatically translates into better memory
- the molecule prevents Alzheimer’s disease
- the effect observed in rats is achieved with a product bought online
- the proposed mechanism guarantees long-term safety
BDNF is not a neuroplasticity button you can press without consequences. Its expression varies with tissue, timing, dose and physiological context. A molecular hypothesis never replaces a measured clinical benefit.
The “1,000 times more potent” myth
The phrase is appealing because it attaches a spectacular number to a complex question. It generally compares quantities administered in certain models, not cognitive improvement measured on a common scale.
Pharmacological potency, efficacy and safety are three different concepts:
| Concept | What it means | What it does not prove |
|---|---|---|
| Activity at a low dose | A smaller quantity produces a defined effect in a model | A stronger subjective effect |
| Clinical efficacy | A useful outcome in the population studied | Efficacy in every population |
| Safety margin | Gap between beneficial exposure and harmful exposure | That a low dose is sufficiently safe |
Saying that Noopept is “1,000 times more potent than piracetam” without specifying the model, outcome and population is therefore misleading. It does not help you choose a product, estimate a dose or predict a memory gain.
Noopept’s legality in France: why “grey area” is a bad answer
The French Public Medicines Database covers medicines marketed or that have been marketed during the last three years in France. On 13 October 2026, searches by name and active substance returned no results for Noopept, omberacetam or ombéracétam. Its scope is not an exhaustive inventory of all historical authorisations. By contrast, it does list NOOTROPYL 800 mg, containing piracetam, as a List II medicine with valid authorisation.
Three practical rules follow from this:
- Not being a narcotic does not mean it can be freely marketed. Medicines law is not limited to the list of narcotics.
- A powder sold as a “research chemical” does not acquire dietary supplement status. This label provides no evidence of authorisation for human consumption.
- Personal use does not mean importation is automatically authorised. The rules vary depending on the import route and the medicine’s status in its country of origin.
L’Article R5121-108 of the French Public Health Code establishes the requirement for authorisation for medicines without appropriate authorisation or registration. The ANSM factsheet on importation by an individual, dated March 2016, specifies that importation by post without prior authorisation is subject to conditions. It may depend, in particular, on marketing authorisation or registration in a European Economic Area state. For a medicine from a third country, local authorisation and a prescription from a doctor practising in that country may be required. In other situations, prior ANSM authorisation remains necessary. Article R5121-110 distinguishes personal transport from shipment and allows the ANSM to prohibit an import presenting a risk, even where an exemption applies.
The phrase “online purchases are tolerated” erases all these conditions. For a specific situation, ask the ANSM or customs for an answer rather than relying on a seller.
Is Noopept authorised in the European Union?
The official laboratories’ report coordinated by the EDQM, published in June 2025, states that Noopept use is not authorised in the European Union. It describes its presence in tested products and raw materials, often presented as nootropics. A website accepting an order from France does not give you a right to use it.
This source is European, but it does not constitute a criminal-law ruling on possession in each member state. During the check on 13 October 2026, no new authorisation was identified in the official sources consulted. Dietary supplement status cannot be inferred from either the name “research chemical” or a foreign marketing authorisation. For a specific product, have the competent authority confirm its classification and the applicable rules.
Buying Noopept online: the risk starts before the pharmacological effect
I do not recommend any seller for an unvalidated cognitive use. Outside an authorised pharmaceutical supply chain, the name on the packet is not enough to establish the contents’ identity. A certificate of analysis sent by the seller does not, on its own, guarantee batch sampling, laboratory independence or the chain of custody.
Quality risks include the following:
- a substance different from the one advertised
- actual dosage far from the label claim
- cross-contamination or residual solvents
- a fake certificate or an analysis of a different batch
- a product degraded by transport or storage
This problem makes self-experimentation difficult to interpret. An effect, lack of effect or symptom cannot be reliably attributed to omberacetam if its identity and quantity are not guaranteed.
What Noopept dosage, and what risks with sublingual use?
Websites and forums often recommend doses measured in milligrams, administration under the tongue and cycles lasting several weeks. These recipes mix foreign product information, preclinical extrapolations and testimonials.
There is no validated dose in France for cognitive enhancement in a healthy person. Giving a precise protocol would create false reassurance when several parameters remain unknown:
- the product’s purity and concentration
- pharmacokinetics for the route used
- interactions with medicines, stimulants or other nootropics
- risk in people with anxiety, high blood pressure or neurological vulnerability
- the safety of repeated or long-term exposure
Sublingual administration is not automatically safer because it bypasses part of the digestive tract. On the contrary, it may alter exposure without the user having reliable data.
If you have already consumed a product presented as Noopept and experience an unusual symptom, do not try to “fix” it with a stack. Contact a healthcare professional or poison control centre, and keep the packaging or batch if possible.
Side effects and interactions: the absence of data is not reassuring
The lack of robust clinical trials prevents establishing a reliable frequency of Noopept’s adverse effects in healthy adults. Lists from forums, such as irritability, headaches, insomnia or brain fog, are anecdotal signals. They allow neither calculation of a risk nor identification of a mechanism.
Extreme caution is needed in the following situations:
- pregnancy, breastfeeding or planning a pregnancy
- age under 18 years
- a history of seizures, bipolar disorder, psychosis or severe anxiety
- cardiovascular, kidney or liver disease
- taking psychostimulants, antidepressants, anticoagulants or neurological medicines
- combining several nootropics or products of uncertain purity
This list does not mean the product is safe in other circumstances. It only identifies contexts where the uncertainty is even less acceptable.
Choline is not an antidote
The idea that you “must” combine it with Alpha-GPC or CDP-choline mainly comes from racetam communities. No robust trial shows that this combination prevents Noopept headaches or improves its benefit–risk balance.
Adding choline can cause its own adverse effects and makes identifying a reaction more difficult. A stack does not turn an unverified product into a controlled clinical intervention. The guide to citicoline and memory · FR assesses this choline precursor separately, without making it a mandatory companion.
Noopept vs piracetam: which is better documented?
Piracetam is much older and far more extensively studied. In France, NOOTROPYL 800 mg is a prescription medicine with valid marketing authorisation. The public database lists specific indications, including certain chronic age-related disorders and symptomatic treatment of vertigo. It also reports an insufficient medical benefit for several authorised indications in the cited assessment.
Medical authorisation does not mean that piracetam improves performance in a healthy adult. A 2024 meta-analysis of adults with memory disorders found no statistically clear clinical difference in memory improvement compared with placebo, with high heterogeneity.
Here is the useful comparison:
| Criterion | Noopept or omberacetam | Piracetam |
|---|---|---|
| Chemical family | Synthetic compound derived from a dipeptide | Racetam, pyrrolidone derivative |
| Status in France | No French marketing authorisation identified | List II prescription medicine with valid marketing authorisation |
| Human data | Very scarce, mainly in cognitive disorders of organic origin | Numerous but old and heterogeneous depending on the indication |
| Evidence in healthy adults | Not established | Not established for routine cognitive enhancement |
| Documented safety | Insufficient, especially long-term | Package leaflet, contraindications and pharmacovigilance available |
| Product quality | Uncertain outside an authorised supply chain | Pharmaceutical quality control for the dispensed medicine |
| Self-experimentation | Not advisable based on the evidence | A prescription medicine should not be used outside its indication |
The answer to “Noopept or piracetam?” is therefore not “whichever is more potent”. For a healthy adult looking to work faster, neither has sufficient evidence to justify self-medication. For a medical indication, only a professional can assess piracetam within the scope of its marketing authorisation, contraindications and kidney function.
The French piracetam package leaflet mentions precautions or contraindications particularly in cases of severe renal impairment, cerebral haemorrhage and clotting disorders. It also reports effects such as nervousness, drowsiness, insomnia, digestive problems or bleeding at varying frequencies. This is not a harmless supplement.
What should you do if your memory or focus declines?
A persistent cognitive decline first needs an explanation, not an experimental nootropic. The Assurance Maladie describes several possible causes of memory problems, including sleep disorders, depression, certain medications, alcohol and severe nutritional deficiencies. If ADHD is suspected, distinguish complementary approaches from promises of natural Ritalin before looking for another molecule. To explore a less experimental supplement without promising cognitive gains, compare the evidence for magnesium L-threonate versus bisglycinate.
A more rational decision-making process looks like this:
- Define the problem. Unstable attention, forgetting information, fatigue, drowsiness and loss of motivation are not the same symptom.
- Track the basics for two weeks. Sleep duration, sleep schedule, alcohol, caffeine, physical activity and periods when you feel a dip.
- Seek medical advice if the problem persists, worsens or interferes with daily life. A medical assessment can look for a treatable cause.
- Choose an intervention whose risk is proportionate to the problem. A sleep routine, exercise and a learning strategy offer a better balance of evidence and risk than an unauthorised powder.
To work on memorisation without an experimental molecule, start with the Feynman technique · FR and our guide to adult neuroplasticity · FR.
The Verdict
Noopept is an interesting research compound, surrounded by a level of certainty that simply does not exist. Mechanisms in rats and cell models demonstrate neither memory gains in healthy adults, nor prevention of cognitive decline, nor long-term safety.
In France, the lack of an identified marketing authorisation and the import rules mean its status cannot be summed up as a “tolerated grey area”. In practical terms, the online market adds a quality problem before you even get to the pharmacological question.
Compared with piracetam, Noopept is not the more modern winner. Piracetam has medical status and more data behind it, but that does not validate its misuse for focus. For a healthy person, the most honest conclusion remains the same: cognitive benefits have not been demonstrated, and the uncertainties do not justify recommending self-experimentation.
